Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Lowered by Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday,Zacks.com reports.

PBH has been the subject of a number of other research reports. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Stock Down 0.2%

PBH stock opened at $46.49 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $89.24. The company has a 50-day moving average of $57.03 and a two-hundred day moving average of $61.17. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of 11.89, a price-to-earnings-growth ratio of 1.50 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The company had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. During the same quarter in the previous year, the business posted $1.32 EPS. The firm’s quarterly revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities research analysts anticipate that Prestige Consumer Healthcare will post 4.43 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds have recently modified their holdings of PBH. Dimensional Fund Advisors LP increased its holdings in shares of Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after purchasing an additional 91,710 shares in the last quarter. State Street Corp boosted its stake in Prestige Consumer Healthcare by 1.4% in the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after acquiring an additional 27,721 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after acquiring an additional 21,085 shares during the last quarter. Morgan Stanley boosted its stake in Prestige Consumer Healthcare by 6.3% in the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after acquiring an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after acquiring an additional 35,126 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).